ERNATIONAL SEARCH REPORT

International Application No. PCT/EP2004/009210

Relevant to claim No.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N9/64 C12Q1/37 A61K38/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, Sequence Search

Category | Citation of document, with indication, where appropriate, of the relevant passages

Calegory	Chancil of docoment, with indication, where appropriate, or the rele	ricievant lo ciamirilo.		
X	WO 02/055702 A (CURAGEN CORP.) 18 July 2002 (2002-07-18) page 5, line 5 - page 10, line 17 page 52 - page 56 table 7c claims 1-41	1-26		
X	WO 02/097438 A (MOUNT SINAI HOSPI 5 December 2002 (2002-12-05) the whole document	TAL)	18-26	
"A" docum consid "E" earlier filling o "L" docum which	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or its cited to establish the publication date of another	T later document published after the interest or priority date and not in conflict with a cited to understand the principle or the invention "X" document of particular relevance; the cited cannot be considered novel or cannot involve an inventive step when the doc "Y" document of particular relevance; the cited and the principle of the document of particular relevance; the cited and the principle of the document of particular relevance; the cited and the principle of the document of particular relevance; the cited and the principle of the document of particular relevance; the cited and the principle of the document of particular relevance; the cited and the principle of the document of particular relevance; the cited and the principle of the document of the docu	mational filing date the application but tory underlying the laimed invention be considered to current is taken alone	
citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but		cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
	actual completion of the international search February 2005	Date of mailing of the international sear 0 2 05. 20		
Name and	mailing address of the ISA European Palent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Giry, M		



International Application No
PCT/EP2004/009210

		<u> </u>
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	In the other blanching big
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NAKAMURA T. ET AL.: "Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues." UROLOGY, vol. 61, no. 5, May 2003 (2003-05), pages 1042-1046, XP002316790 the whole document	18-26
Α	YU H. ET AL.: "Association of the tissue kallikrein gene promoter with ESRD and hypertension." KIDNEY INT., vol. 61, 2002, pages 1030-1039, XP002316791 the whole document	1-26
A	MERLO C. ET AL.: "Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease." ATHEROSCLEROSIS, vol. 161, 2002, pages 261-267, XP002316792 the whole document	1-26

INTERNATIONAL SEARCH REPORT

International application No. PCT/EP2004/009210

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. X Claims Nos.: 26 because they relate to subject matter not required to be searched by this Authority, namely:					
Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.					
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:					
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
see additional sheet					
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. .					
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-26 (all partially)					
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of cardiovascular diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

2. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of urological diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

3. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of endocrinological diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

4. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of metabolic diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

5. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of reproduction disorders, method of diagnosing said disorders, and pharmaceutical compositions for the treatment of said disorders, all using KLK11 as a target.

6. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of dermatological diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

7. claims: 1-26 (all partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Method of screening for therapeutic agents useful in the treatment of respiratory diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

8. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of gastroenterological diseases, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.

9. claims: 1-26 (all partially)

Method of screening for therapeutic agents useful in the treatment of cancer disorders, method of diagnosing said diseases, and pharmaceutical compositions for the treatment of said diseases, all using KLK11 as a target.



Information on patent family members

International Application No PCT/EP2004/009210

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 02055702	A	18-07-2002	CA EP JP WO US	2426588 A1 1407018 A2 2004532613 T 02055702 A2 2004024181 A1	18-07-2002 14-04-2004 28-10-2004 18-07-2002 05-02-2004
WO 02097438	A	05-12-2002	WO CA EP JP US	02097438 A1 2448355 A1 1390756 A1 2004530884 T 2004203012 A1	05-12-2002 05-12-2002 25-02-2004 07-10-2004 14-10-2004